Close
Nordic 9Nordic 9

Cancer Research Horizons (investor - Corporate Investor)

United Kingdom cancerresearchhorizons.com
See something wrong or missing? Let us know
Offices:London

Cancer Research Horizons is a British specialist drug discovery, development and commercialisation company

Average round investment:27.32M USD
Average number per year:1.5
Distribution: 2026 (1)2025 (2)2024 (2)2023 (1)
Portfolio companies: United Kingdom InfinitopesNetherlands Laigo BioUnited Kingdom Trogenix See the entire list
Mostly invests in: United Kingdom United Kingdom (5) Health services (6)
See the entire list

Showing 3 of 6 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Cancer Research Horizons

Name Criteria
United States Illumina Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Software Services, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United States WAVE Equity Partners
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Software Services, Hardware
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United States Coefficient Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United States Radius Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Software Services, Hardware
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United States Engine Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Software Services, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Spain We Venture Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Software Services, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United States CourtsideVC
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.4
  • Active last 12 months: Yes
Japan Asahi Kasei
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Pharma, Manufacturing, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
United States Upfront Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Software Services, Hardware
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Sweden MW Group
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Software Services, Hardware
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Top